INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Seneca Biopharma, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims
13 févr. 2020 12h50 HE
|
Fields Kupka & Shukurov LLP
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential securities violations and breach of fiduciary duty claims involving the board of directors of...
T1D Exchange Names New Board Members
11 déc. 2018 07h45 HE
|
T1D Exchange
BOSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- T1D Exchange, a nonprofit, research organization dedicated to accelerating therapies and improving care for people affected by type 1 diabetes, today...
Neuralstem Added to the Russell Microcap® Index
26 juin 2017 08h32 HE
|
Neuralstem, Inc.
GERMANTOWN, Md., June 26, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has...
Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder
17 mai 2017 16h05 HE
|
Neuralstem, Inc.
GERMANTOWN, Md., May 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, today announced it has...
Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
10 mai 2017 16h05 HE
|
Neuralstem, Inc.
GERMANTOWN, Md., May 10, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, reported its financial...
Neuralstem to Present at 29th Annual ROTH Conference
08 mars 2017 07h03 HE
|
Neuralstem, Inc.
GERMANTOWN, Md., March 08, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell...
Neuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular Physiology
28 févr. 2017 07h03 HE
|
Neuralstem, Inc.
-NSI-189 Showed Durable Functional Recovery in a Rodent Model of Ischemic Stroke- -NSI-189 Promoted Synaptic Remodeling After Stroke- GERMANTOWN, Md., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Neuralstem,...
Neuralstem Announces Issuance of U.S. Patent Covering NSI-189
22 févr. 2017 07h03 HE
|
Neuralstem, Inc.
GERMANTOWN, Md., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem...
Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder
16 févr. 2017 07h02 HE
|
Neuralstem, Inc.
- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development...
Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.
12 déc. 2016 07h38 HE
|
Neuralstem, Inc.
GERMANTOWN, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural...